ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCCN Publishes Anemia Guidelines

April 12, 2002

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

Cancer Statistics: Colorectal Cancer Incidence Declines, Annual Report Finds

May 19, 2000

Congress Insists On No Downward Negotiations; NCI May Drop 2000 To 300 Grants In FY 1991

November 9, 1990

Reimbursement: NCI, VA Begin Project On Clinical Trials Access For Veterans

January 17, 1997

NCI Health Disparities Center Describes “Think Tank” Projects For Policy Change.

April 27, 2001